These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36045021)

  • 1. Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials.
    Dixon JG; Çağlayan Ç; Chihara D; Nielsen T; Dimier N; Zheng J; Wall AK; Salles G; Morschhauser F; Marcus R; Herold M; Kimby E; Blum KA; Ghielmini M; Shi Q; Flowers CR
    Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e1009-e1018. PubMed ID: 36045021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the Effectiveness of Treatment Sequences for Older Patients With High-risk Follicular Lymphoma With a Multistate Model.
    Çağlayan Ç; Terawaki H; Ayer T; Goldstein JS; Rai A; Chen Q; Flowers C
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):300-309.e5. PubMed ID: 30686772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
    Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
    Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study.
    Wu JQ; Song YP; Su LP; Zhang MZ; Li W; Hu Y; Zhang XH; Gao YH; Niu ZX; Feng R; Wang W; Peng JW; Li XL; Ouyang XN; Wu CP; Zhang WJ; Zeng Y; Xiao Z; Liang YM; Zhuang YZ; Wang JS; Sun ZM; Bai H; Cui TJ; Feng JF
    Chin Med J (Engl); 2018 Aug; 131(15):1767-1775. PubMed ID: 30058572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
    Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
    Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.
    Vidal L; Gafter-Gvili A; Salles G; Bousseta S; Oberman B; Rubin C; van Oers MH; Fortpied C; Ghielmini M; Pettengell R; Witzens-Harig M; Dreger P; Vitolo U; Gomes da Silva M; Evangelista A; Li H; Freedman L; Habermann TM; Shpilberg O
    Eur J Cancer; 2017 May; 76():216-225. PubMed ID: 28336303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States.
    Nastoupil LJ; Sinha R; Byrtek M; Zhou X; Taylor MD; Friedberg JW; Link BK; Cerhan JR; Dawson K; Flowers CR
    Cancer; 2014 Jun; 120(12):1830-7. PubMed ID: 24668580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
    Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
    Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis.
    Al Khabori M; de Almeida JR; Guyatt GH; Kuruvilla J; Crump M
    J Natl Cancer Inst; 2012 Jan; 104(1):18-28. PubMed ID: 22190633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.
    Vidal L; Gafter-Gvili A; Leibovici L; Dreyling M; Ghielmini M; Hsu Schmitz SF; Cohen A; Shpilberg O
    J Natl Cancer Inst; 2009 Feb; 101(4):248-55. PubMed ID: 19211444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab maintenance improves overall survival in follicular lymphoma: A retrospective nationwide real-world analysis from Taiwan Cancer Registry Database.
    Huang HH; Wen YC; Chen HM; Hsiao FY; Ko BS
    Cancer Med; 2018 Aug; 7(8):3582-3591. PubMed ID: 30009424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy.
    Murakami S; Kato H; Higuchi Y; Yamamoto K; Yamamoto H; Saito T; Taji H; Yatabe Y; Nakamura S; Kinoshita T
    Ann Hematol; 2016 Aug; 95(8):1259-69. PubMed ID: 27220639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical features and outcomes of newly diagnosed follicular lymphoma concurrent with diffuse large B-cell lymphoma component].
    Lin ZJ; Zha J; Yi SH; Li ZF; Ping LY; He XH; Yu HF; Zheng Z; Xu W; Chen FL; Xie Y; Chen BY; Zhang HL; Wang L; Ding KY; Li WY; Yang HY; Zhao WL; Qiu LG; Li ZM; Song YQ; Xu B
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):456-462. PubMed ID: 35968587
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis.
    Police RL; Trask PC; Wang J; Olivares R; Khan S; Abbe A; Colosia A; Njue A; Sherril B; Ruiz-Soto R; Kaye JA; Hamadani M
    J Oncol Pharm Pract; 2016 Oct; 22(5):666-78. PubMed ID: 26320127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group.
    Provencio M; Royuela A; Torrente M; Pollán M; Gómez-Codina J; Sabín P; Llanos M; Gumá J; Quero C; Blasco A; Aguiar D; García-Arroyo FR; Lavernia J; Martínez N; Morales M; Saenz-Cusi Á; Rodríguez D; Calvo V; de la Cruz-Merino L; de la Cruz MÁ; Rueda A;
    Cancer; 2017 Oct; 123(19):3709-3716. PubMed ID: 28608996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials.
    Casulo C; Dixon JG; Ou FS; Hoster E; Peterson BA; Hochster HS; Brice P; Ladetto M; Hiddemann W; Marcus R; Kimby E; Herold M; Nielsen T; Morschhauser F; Rummel M; Hagenbeek A; Vitolo U; Salles GA; Shi Q; Flowers CR
    Blood Adv; 2021 Mar; 5(6):1737-1745. PubMed ID: 33749762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.